Company Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Why Investors Should Care
Net profit has compounded at 19.7% per year over the last five years.
Revenue has grown at a 20.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.98M (+19.0% YoY); net profit $-2.68M.
- Trailing 12 Months Year-on-year growth — revenue +36.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.4%, profit CAGR 19.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.36% |
| 1 Year: | 36.00% |
Compounded Profit Growth
| 5 Years: | 19.70% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -21.15% |
| 6 Months: | +8.80% |
| 3 Months: | -16.34% |
| 1 Month: | -13.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.4% over 5 years.
- Profit CAGR of 19.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 75.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XBIO Xenetic Biosciences, Inc. | 2.54 | -2.13 | $5.81M | 0.00% | -38.33% | -37.01% | 20.36% | 19.70% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 593.26K | 589.90K | 1.03M | 766.30K | 806.92K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 1.54M | 1.31M | 1.57M | 1.39M | 1.31M |
| Operating Income | -942.41K | -724.41K | -544.73K | -623.03K | -502.12K |
| EBITDA | -942.41K | -724.41K | -544.73K | -623.03K | -502.12K |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -903.14K | -688.70K | -509.94K | -579.08K | -456.38K |
| Tax Provision | - | - | - | - | - |
| Net Income | -903.14K | -688.70K | -509.94K | -579.08K | -456.38K |
| Diluted EPS | -0.59 | -0.45 | -0.33 | - | -0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.71M | 2.54M | 2.50M | 2.98M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 8.42M | 7.06M | 6.70M | 5.81M |
| Operating Income | - | -6.72M | -4.52M | -4.20M | -2.83M |
| EBITDA | - | -6.69M | -4.52M | -4.20M | -2.83M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -6.55M | -4.13M | -3.96M | -2.68M |
| Tax Provision | 0 | - | - | - | - |
| Net Income | - | -6.55M | -4.13M | -3.96M | -2.68M |
| Diluted EPS | - | -4.61 | -2.71 | -2.57 | -1.58 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 14.72M | 10.61M | 6.90M | 8.36M |
| Current Assets | - | 13.65M | 9.59M | 6.59M | 8.05M |
| Cash & Equivalents | - | 13.10M | 8.98M | 6.17M | 7.88M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 1.07M | 809.59K | 894.26K | 968.02K |
| Current Liabilities | - | 1.07M | 809.59K | 894.26K | 968.02K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 13.65M | 9.80M | 6.01M | 7.40M |
| Shares Outstanding | - | 1.52M | 1.54M | 1.54M | 2.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.65M | -4.11M | -2.82M | -2.29M |
| Investing Cash Flow | 0 | -500.00K | 0 | - | - |
| Financing Cash Flow | 11.45M | 0 | - | 0 | 4.00M |
| Capital Expenditure | - | -500.00K | - | - | - |
| Free Cash Flow | - | -5.15M | -4.11M | -2.82M | -2.29M |
| Net Change in Cash | - | -5.15M | -4.11M | -2.82M | 1.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -393.6% | -177.8% | -168.2% | -95.2% |
| Net Margin % | - | -383.9% | -162.8% | -158.4% | -90.1% |
| ROE % | - | -48.0% | -42.2% | -65.9% | -36.2% |
| ROCE % | - | -49.2% | -46.1% | -70.0% | -38.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 6.00% | 137.44K | $348.41K |
| 2 | Geode Capital Management, LLC | 0.94% | 21.44K | $54.35K |
| 3 | Vanguard Capital Management LLC | 0.29% | 6.73K | $17.06K |
| 4 | JTC Employer Solutions Trustee Ltd. | 0.12% | 2.70K | $6.84K |
| 5 | Tower Research Capital LLC (TRC) | 0.04% | 806 | $2.04K |
| 6 | SBI Securities Co., Ltd. | 0.04% | 1.00K | $2.54K |
| 7 | Darwin Wealth Management, LLC | - | 2 | $5 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XBIO
XBIO — Frequently Asked Questions
What is the current share price of Xenetic Biosciences, Inc. (XBIO)?
As of 2026-08-02 19:16 PDT, Xenetic Biosciences, Inc. (XBIO) trades at $2.54 on NasdaqCM. Its 52-week range is $2.02 to $10.36.
What is the market capitalisation of XBIO?
Xenetic Biosciences, Inc. (XBIO) has a market capitalisation of $5.81M on NasdaqCM.
What is the P/E ratio of XBIO?
XBIO trades at a trailing price-to-earnings (P/E) ratio of -2.13. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.84.
What is the return on equity (ROE) of XBIO?
XBIO has a return on equity (ROE) of -37.01%. Its return on capital employed (ROCE) is -38.33%.
Is XBIO a good stock to buy?
This page provides a data-driven analysis of Xenetic Biosciences, Inc. (XBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.